ASIA PACIFIC GERD DRUGS AND DEVICES MARKET FORECAST 2019-2027

ASIA PACIFIC GERD DRUGS AND DEVICES MARKET FORECAST 2019-2027

  • November 2018 •
  • 85 pages •
  • Report ID: 5626020 •
  • Format: PDF
KEY FINDINGS
The APAC region market for GERD drugs and devices account growth of 1.52% CAGR through the forecasted years of 2019-2027. This region includes Japan, China, India, South Korea, Australia and the Rest of Asia.

MARKET INSIGHTS
The largest revenue contributor to the APAC market for GERD drugs and devices are Japan, China and India because of driving factors like availability of fewer approved drugs to treat GERD and increasing awareness about GERD among the patients that are pushing the growth of this market.

COMPETITIVE INSIGHTS
Some of the companies that provides additional revenue of the global GERG drugs and devices market are Abbott Laboratories, AstraZeneca, Ausch Health (Formerly Valeant Pharmaceuticals International, Inc.), Boston Scientific Corporation, Cempra Inc. (Merged with Melinta), Daewoong Co. Ltd., Eisai Inc., Glaxosmithkline, Ironwood Pharmaceuticals, Inc., Johnson & Johnson, Merck & Co. Inc., Novartis, Pfizer, Inc., RaQualia Pharma Inc. and Takeda Pharmaceuticals Company Limited.

Companies mentioned
1. ABBOTT LABORATORIES.
2. ASTRAZENECA
3. BAUSCH HEALTH (FORMERLY VALEANT PHARMACEUTICALS INTERNATIONAL, INC.)
4. BOSTON SCIENTIFIC CORPORATION
5. CEMPRA INC. (MERGED WITH MELINTA)
6. DAEWOONG CO. LTD.
7. EISAI INC
8. GLAXOSMITHKLINE
9. IRONWOOD PHARMACEUTICALS, INC.
10. JOHNSON & JOHNSON
11. MERCK & CO., INC.
12. NOVARTIS
13. PFIZER, INC.
14. RAQUALIA PHARMA INC.
15. TAKEDA PHARMACEUTICALS COMPANY LIMITED